| Literature DB >> 33937245 |
Yang Liu1, Xiaotong Zhao1, Bing Wang2, Zhijia Liu1, Manman Zhang1, Jinhan Wang1, Chang Xu1, Yan Wang1, Liqing Du1, Feng Wang2, Qin Wang1, Qiang Liu1.
Abstract
CTC1 is a component of the mammalian CST (CTC1-STN1-TEN1) complex which plays essential roles in resolving replication problems to facilitate telomeric DNA and genomic DNA replication. We previously reported that the depletion of CTC1 leads to stalled replication fork restart defects. Moreover, the mutation in CTC1 caused cancer-prone diseases including Coats plus (CP) or dyskeratosis congenita (DC). To better understand the CTC1 regulatory axis, the microRNAs (miRNAs) targeting to CTC1 were predicted by a bioinformatics tool, and the selected candidates were further confirmed by a dual-luciferase reporter assay. Here, our current results revealed that miR-376a significantly reduced CTC1 expression at the transcription level by recognizing CTC1 3'-UTR. In addition, the overexpression of miR-376a induced telomere replication defection and resulted in direct replicative telomere damage, which could be rescued by adding back CTC1. Telomere shortening was also observed upon miR-376a treatment. Furthermore, for the clinical patient samples, the high expression of miR-376a was associated with the deregulation of CTC1 and a poor outcome for the rectum adenocarcinoma patients. Together, our results uncovered a novel role of miR-376a in stimulating rectum adenocarcinoma progression via CTC1 downregulating induced telomere dysfunction.Entities:
Keywords: CST; miR-376a; microRNA; rectum adenocarcinoma; telomere
Year: 2021 PMID: 33937245 PMCID: PMC8085492 DOI: 10.3389/fcell.2021.649328
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Several microRNAs (miRNAs) were identified to target CTC1. (A) Dual-luciferase assay report of HEK293T cells that expressed the indicated miRNA targeting the CTC1 3′-UTR. (B) List of candidate miRNAs tested by the luciferase assay and the number of miRanda screening read sites. (C) Predicated binding sites of miR-376a and miR-29a on the CTC1 3′-UTR. Mutant sites in the seed region were labeled in red. (D) Luciferase activity of cells expressing the wild-type CTC1 or mutant CTC1 3′-UTR with the selected miRNAs. P values were determined by Student’s t test. An asterisk was annotated on the panel if the statistical P < 0.05 compared to the control.
FIGURE 2Selected microRNAs (miRNAs) could induce telomere dysfunction via downregulating CTC1 expression. (A) The relative CTC1 messenger RNA (mRNA) transcriptional level was determined by quantitative real-time PCR in the control and the miRNA or short hairpin RNA (shRNA) treatment groups. The expression difference was calculated by one-way ANOVA, with *P < 0.05 and **P < 0.01. (B) The protein level was evaluated by Western blot assay upon miRNA or shRNA treatment. The relative gray value was annotated below each panel. (C) The growth curve upon miRNA or shRNA treatment was determined by cell counting. (D) Representative images of metaphase telomere fluorescence in situ hybridization (FISH) upon different treatments. Multi-telomeric signal (MTS) is indicated by the white arrows. The red florescence exhibits telomere FISH signal while chromosomes were stained with DAPI (blue). (E) The percentage of chromosomes with MTS was calculated upon miRNA or shRNA treatment based on the FISH results as demonstrated in panel (D). Statistical analysis was calculated by one-way ANOVA, with *P < 0.05.
FIGURE 3miR-376a leads to telomere damage, which relies on CTC1 expression and ataxia-telangiectasia-mutated-and-Rad3-related kinase (ATR) signal pathway activation. (A) Representative image showing the telomere dysfunction-induced foci (TIFs) on interphase cells with different treatments. TIFs are labeled with white arrows. Telomere (green), 53BP1 (red), and nuclei were stained with DAPI (blue). (B) The percentage of cells with more than four TIFs was calculated. (C) Graph showing the number of 53BP1 foci under different conditions. P values were determined by one-way ANOVA, with *P < 0.05.
FIGURE 4miR-376a causes telomere shortening independent of telomerase. (A) Telomere length was determined by TRF Southern blot; the mean telomere length in each treatment group was labeled by the circle in the lane. (B) The telomere length was calculated and graphed based on the image in graph (A). (C) Telomerase activity determined by TRAP assay is demonstrated. (D) The telomerase activity among different treatment groups was calculated and graphed. Statistical analysis was determined by one-way ANOVA, with *P < 0.05.
FIGURE 5miR-376a induces genomic DNA replication deficiency. (A) Genomic DNA replication efficiency determined by 5-ethynyl-2′-deoxyuridine (EdU) incorporation. Incorporated EdU (green) and nuclei stained with DAPI (blue). (B) The relative EdU incorporation in the different treatment groups was calculated and statistically analyzed. (C) Representative images of normal nuclei and micronuclei. (D) The number of cells with micronuclei in each treatment group was calculated and the statistics of percent of cells with micronuclei was determined by one-way ANOVA. *P < 0.05 and **P < 0.01.
FIGURE 6miR-376a expression is correlated with CTC1 deregulation and poor outcomes in rectum adenocarcinoma patients. (A) The CTC1 messenger RNA (mRNA) transcription in rectum adenocarcinoma tumor and normal tissues was analyzed. The mRNA transcriptional data was obtained from the GEPIA2 database, with 92 tumor and 318 normal samples included. (B) The overall survival rates of rectum adenocarcinoma patients with high or low levels of CTC1 were demonstrated based on the 92 tumor patients from the GEPIA2 database. (C,D) The mRNA samples of tumor tissue and adjacent tissues from six rectum adenocarcinoma patients were obtained. The transcriptional levels of CTC1 and miR-376a were determined by quantitative real-time PCR. (E) The inverse relation between CTC1 and miR-376a was also observed based on the transcriptional levels of the 12 samples from the tumor and adjacent tissues of the six rectum adenocarcinoma patients tested in our current study.